Sanofi European study of nirsevimab to protect babies against RSV starts enrolling

Aug. 12, 2022 9:52 AM ETSanofi (SNY)AZN, LHBy: Ravikash, SA News Editor

Respiratory Syncytial Virus RSV handwriting text on paper, on office agenda. Copy space.

vladispas/iStock via Getty Images

  • Sanofi (NASDAQ:SNY) said the first patient was enrolled in a European study of the company and AstraZeneca's (AZN) antibody nirsevimab to prevent hospitalizations due to Respiratory syncytial virus (RSV) in infants under 12 months of age.
  • The study, dubbed HARMONIE, is being carried out under a collaboration between the National Institute for Health and Care Research (NIHR), Sanofi and clinical research organisation partner Labcorp (LH).
  • Sanofi added that that more than 20K infants will be enrolled across 280 sites in the U.K., France and Germany between August 2022 to March 2023, of which the majority (up to 12K) will be U.K. infants.
  • In May, AstraZeneca and Sanofi reported data showing efficacy of single dose nirsevimab against lower respiratory tract infections (LRTI), caused by RSV in infants.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.